nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Cloperastine—Raloxifene—breast cancer	0.701	1	CrCrCtD
Trihexyphenidyl—Tension—Goserelin—breast cancer	0.000727	0.00378	CcSEcCtD
Trihexyphenidyl—Hallucination—Thiotepa—breast cancer	0.000725	0.00377	CcSEcCtD
Trihexyphenidyl—Nervousness—Goserelin—breast cancer	0.00072	0.00375	CcSEcCtD
Trihexyphenidyl—Confusional state—Chlorambucil—breast cancer	0.000717	0.00373	CcSEcCtD
Trihexyphenidyl—Nausea—Fulvestrant—breast cancer	0.000712	0.00371	CcSEcCtD
Trihexyphenidyl—Weight decreased—Irinotecan—breast cancer	0.000711	0.0037	CcSEcCtD
Trihexyphenidyl—Weight decreased—Mitoxantrone—breast cancer	0.000711	0.0037	CcSEcCtD
Trihexyphenidyl—Asthenia—Ixabepilone—breast cancer	0.000705	0.00367	CcSEcCtD
Trihexyphenidyl—Nausea—Toremifene—breast cancer	0.000703	0.00366	CcSEcCtD
Trihexyphenidyl—Drowsiness—Mitoxantrone—breast cancer	0.000701	0.00365	CcSEcCtD
Trihexyphenidyl—Vision blurred—Goserelin—breast cancer	0.000699	0.00363	CcSEcCtD
Trihexyphenidyl—Dizziness—Exemestane—breast cancer	0.000689	0.00358	CcSEcCtD
Trihexyphenidyl—Dry skin—Paclitaxel—breast cancer	0.00068	0.00354	CcSEcCtD
Trihexyphenidyl—Asthenia—Letrozole—breast cancer	0.000664	0.00346	CcSEcCtD
Trihexyphenidyl—Asthenia—Anastrozole—breast cancer	0.000664	0.00346	CcSEcCtD
Trihexyphenidyl—Vomiting—Exemestane—breast cancer	0.000662	0.00345	CcSEcCtD
Trihexyphenidyl—Rash—Exemestane—breast cancer	0.000657	0.00342	CcSEcCtD
Trihexyphenidyl—Dermatitis—Exemestane—breast cancer	0.000656	0.00341	CcSEcCtD
Trihexyphenidyl—Headache—Exemestane—breast cancer	0.000653	0.0034	CcSEcCtD
Trihexyphenidyl—Dizziness—Ixabepilone—breast cancer	0.00065	0.00338	CcSEcCtD
Trihexyphenidyl—Vomiting—Ixabepilone—breast cancer	0.000625	0.00325	CcSEcCtD
Trihexyphenidyl—Tension—Thiotepa—breast cancer	0.000622	0.00324	CcSEcCtD
Trihexyphenidyl—Rash—Ixabepilone—breast cancer	0.00062	0.00322	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ixabepilone—breast cancer	0.000619	0.00322	CcSEcCtD
Trihexyphenidyl—Nausea—Exemestane—breast cancer	0.000619	0.00322	CcSEcCtD
Trihexyphenidyl—Nervousness—Thiotepa—breast cancer	0.000616	0.0032	CcSEcCtD
Trihexyphenidyl—Headache—Ixabepilone—breast cancer	0.000616	0.0032	CcSEcCtD
Trihexyphenidyl—Dizziness—Anastrozole—breast cancer	0.000612	0.00318	CcSEcCtD
Trihexyphenidyl—Dizziness—Letrozole—breast cancer	0.000612	0.00318	CcSEcCtD
Trihexyphenidyl—Confusional state—Goserelin—breast cancer	0.00061	0.00317	CcSEcCtD
Trihexyphenidyl—Tachycardia—Melphalan—breast cancer	0.000605	0.00315	CcSEcCtD
Trihexyphenidyl—Vision blurred—Thiotepa—breast cancer	0.000598	0.00311	CcSEcCtD
Trihexyphenidyl—Tachycardia—Goserelin—breast cancer	0.00059	0.00307	CcSEcCtD
Trihexyphenidyl—Vomiting—Anastrozole—breast cancer	0.000588	0.00306	CcSEcCtD
Trihexyphenidyl—Vomiting—Letrozole—breast cancer	0.000588	0.00306	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Chlorambucil—breast cancer	0.000586	0.00305	CcSEcCtD
Trihexyphenidyl—Nausea—Ixabepilone—breast cancer	0.000584	0.00304	CcSEcCtD
Trihexyphenidyl—Rash—Anastrozole—breast cancer	0.000584	0.00304	CcSEcCtD
Trihexyphenidyl—Rash—Letrozole—breast cancer	0.000584	0.00304	CcSEcCtD
Trihexyphenidyl—Dermatitis—Letrozole—breast cancer	0.000583	0.00303	CcSEcCtD
Trihexyphenidyl—Dermatitis—Anastrozole—breast cancer	0.000583	0.00303	CcSEcCtD
Trihexyphenidyl—Agitation—Thiotepa—breast cancer	0.000583	0.00303	CcSEcCtD
Trihexyphenidyl—Dizziness—Raloxifene—breast cancer	0.000581	0.00302	CcSEcCtD
Trihexyphenidyl—Headache—Anastrozole—breast cancer	0.00058	0.00302	CcSEcCtD
Trihexyphenidyl—Headache—Letrozole—breast cancer	0.00058	0.00302	CcSEcCtD
Trihexyphenidyl—Weight decreased—Paclitaxel—breast cancer	0.00058	0.00302	CcSEcCtD
Trihexyphenidyl—Dry skin—Docetaxel—breast cancer	0.000576	0.003	CcSEcCtD
Trihexyphenidyl—Vomiting—Raloxifene—breast cancer	0.000559	0.00291	CcSEcCtD
Trihexyphenidyl—Vomiting—Idarubicin—breast cancer	0.000559	0.00291	CcSEcCtD
Trihexyphenidyl—Dry skin—Capecitabine—breast cancer	0.000558	0.0029	CcSEcCtD
Trihexyphenidyl—Constipation—Vinblastine—breast cancer	0.000558	0.0029	CcSEcCtD
Trihexyphenidyl—Rash—Raloxifene—breast cancer	0.000554	0.00288	CcSEcCtD
Trihexyphenidyl—Rash—Idarubicin—breast cancer	0.000554	0.00288	CcSEcCtD
Trihexyphenidyl—Dermatitis—Raloxifene—breast cancer	0.000553	0.00288	CcSEcCtD
Trihexyphenidyl—Dermatitis—Idarubicin—breast cancer	0.000553	0.00288	CcSEcCtD
Trihexyphenidyl—Headache—Raloxifene—breast cancer	0.00055	0.00286	CcSEcCtD
Trihexyphenidyl—Headache—Idarubicin—breast cancer	0.00055	0.00286	CcSEcCtD
Trihexyphenidyl—Nausea—Letrozole—breast cancer	0.00055	0.00286	CcSEcCtD
Trihexyphenidyl—Nausea—Anastrozole—breast cancer	0.00055	0.00286	CcSEcCtD
Trihexyphenidyl—Constipation—Tamoxifen—breast cancer	0.000542	0.00282	CcSEcCtD
Trihexyphenidyl—Somnolence—Goserelin—breast cancer	0.000538	0.0028	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Vinblastine—breast cancer	0.000537	0.0028	CcSEcCtD
Trihexyphenidyl—Tachycardia—Vinorelbine—breast cancer	0.000529	0.00275	CcSEcCtD
Trihexyphenidyl—Biperiden—CYP2D6—breast cancer	0.000526	0.316	CrCbGaD
Trihexyphenidyl—Nausea—Raloxifene—breast cancer	0.000522	0.00271	CcSEcCtD
Trihexyphenidyl—Nausea—Idarubicin—breast cancer	0.000522	0.00271	CcSEcCtD
Trihexyphenidyl—Confusional state—Thiotepa—breast cancer	0.000522	0.00271	CcSEcCtD
Trihexyphenidyl—Constipation—Goserelin—breast cancer	0.000517	0.00269	CcSEcCtD
Trihexyphenidyl—Vision blurred—Mitoxantrone—breast cancer	0.000516	0.00268	CcSEcCtD
Trihexyphenidyl—Asthenia—Chlorambucil—breast cancer	0.00051	0.00266	CcSEcCtD
Trihexyphenidyl—Tachycardia—Thiotepa—breast cancer	0.000505	0.00263	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Goserelin—breast cancer	0.000499	0.00259	CcSEcCtD
Trihexyphenidyl—Vision blurred—Fluorouracil—breast cancer	0.000494	0.00257	CcSEcCtD
Trihexyphenidyl—Weight decreased—Docetaxel—breast cancer	0.000491	0.00256	CcSEcCtD
Trihexyphenidyl—Weight decreased—Capecitabine—breast cancer	0.000476	0.00248	CcSEcCtD
Trihexyphenidyl—Asthenia—Vinblastine—breast cancer	0.000468	0.00243	CcSEcCtD
Trihexyphenidyl—Constipation—Vinorelbine—breast cancer	0.000463	0.00241	CcSEcCtD
Trihexyphenidyl—Somnolence—Thiotepa—breast cancer	0.00046	0.00239	CcSEcCtD
Trihexyphenidyl—Asthenia—Tamoxifen—breast cancer	0.000454	0.00236	CcSEcCtD
Trihexyphenidyl—Vomiting—Chlorambucil—breast cancer	0.000452	0.00235	CcSEcCtD
Trihexyphenidyl—Confusional state—Mitoxantrone—breast cancer	0.000451	0.00234	CcSEcCtD
Trihexyphenidyl—Confusional state—Irinotecan—breast cancer	0.000451	0.00234	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Vinorelbine—breast cancer	0.000446	0.00232	CcSEcCtD
Trihexyphenidyl—Asthenia—Melphalan—breast cancer	0.000445	0.00232	CcSEcCtD
Trihexyphenidyl—Constipation—Thiotepa—breast cancer	0.000442	0.0023	CcSEcCtD
Trihexyphenidyl—Tension—Paclitaxel—breast cancer	0.000438	0.00228	CcSEcCtD
Trihexyphenidyl—Tachycardia—Mitoxantrone—breast cancer	0.000436	0.00227	CcSEcCtD
Trihexyphenidyl—Asthenia—Goserelin—breast cancer	0.000434	0.00226	CcSEcCtD
Trihexyphenidyl—Nervousness—Paclitaxel—breast cancer	0.000434	0.00226	CcSEcCtD
Trihexyphenidyl—Confusional state—Fluorouracil—breast cancer	0.000432	0.00225	CcSEcCtD
Trihexyphenidyl—Dizziness—Vinblastine—breast cancer	0.000431	0.00224	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Thiotepa—breast cancer	0.000426	0.00222	CcSEcCtD
Trihexyphenidyl—Nausea—Chlorambucil—breast cancer	0.000423	0.0022	CcSEcCtD
Trihexyphenidyl—Vision blurred—Paclitaxel—breast cancer	0.000421	0.00219	CcSEcCtD
Trihexyphenidyl—Dizziness—Tamoxifen—breast cancer	0.000419	0.00218	CcSEcCtD
Trihexyphenidyl—Tachycardia—Fluorouracil—breast cancer	0.000418	0.00217	CcSEcCtD
Trihexyphenidyl—Vomiting—Vinblastine—breast cancer	0.000415	0.00216	CcSEcCtD
Trihexyphenidyl—Agitation—Paclitaxel—breast cancer	0.00041	0.00214	CcSEcCtD
Trihexyphenidyl—Oxybutynin—CYP2D6—breast cancer	0.00041	0.246	CrCbGaD
Trihexyphenidyl—Headache—Vinblastine—breast cancer	0.000408	0.00213	CcSEcCtD
Trihexyphenidyl—Vomiting—Tamoxifen—breast cancer	0.000403	0.0021	CcSEcCtD
Trihexyphenidyl—Dizziness—Goserelin—breast cancer	0.0004	0.00208	CcSEcCtD
Trihexyphenidyl—Rash—Tamoxifen—breast cancer	0.000399	0.00208	CcSEcCtD
Trihexyphenidyl—Dermatitis—Tamoxifen—breast cancer	0.000399	0.00208	CcSEcCtD
Trihexyphenidyl—Somnolence—Irinotecan—breast cancer	0.000397	0.00207	CcSEcCtD
Trihexyphenidyl—Somnolence—Mitoxantrone—breast cancer	0.000397	0.00207	CcSEcCtD
Trihexyphenidyl—Headache—Tamoxifen—breast cancer	0.000397	0.00206	CcSEcCtD
Trihexyphenidyl—Vomiting—Melphalan—breast cancer	0.000394	0.00205	CcSEcCtD
Trihexyphenidyl—Rash—Melphalan—breast cancer	0.000391	0.00203	CcSEcCtD
Trihexyphenidyl—Dermatitis—Melphalan—breast cancer	0.000391	0.00203	CcSEcCtD
Trihexyphenidyl—Asthenia—Vinorelbine—breast cancer	0.000389	0.00202	CcSEcCtD
Trihexyphenidyl—Dry skin—Epirubicin—breast cancer	0.000389	0.00202	CcSEcCtD
Trihexyphenidyl—Nausea—Vinblastine—breast cancer	0.000387	0.00201	CcSEcCtD
Trihexyphenidyl—Somnolence—Gemcitabine—breast cancer	0.000387	0.00201	CcSEcCtD
Trihexyphenidyl—Vomiting—Goserelin—breast cancer	0.000385	0.002	CcSEcCtD
Trihexyphenidyl—Constipation—Irinotecan—breast cancer	0.000382	0.00199	CcSEcCtD
Trihexyphenidyl—Constipation—Mitoxantrone—breast cancer	0.000382	0.00199	CcSEcCtD
Trihexyphenidyl—Rash—Goserelin—breast cancer	0.000381	0.00198	CcSEcCtD
Trihexyphenidyl—Dermatitis—Goserelin—breast cancer	0.000381	0.00198	CcSEcCtD
Trihexyphenidyl—Somnolence—Fluorouracil—breast cancer	0.00038	0.00198	CcSEcCtD
Trihexyphenidyl—Headache—Goserelin—breast cancer	0.000379	0.00197	CcSEcCtD
Trihexyphenidyl—Nausea—Tamoxifen—breast cancer	0.000376	0.00196	CcSEcCtD
Trihexyphenidyl—Biperiden—ABCB1—breast cancer	0.000376	0.226	CrCbGaD
Trihexyphenidyl—Constipation—Gemcitabine—breast cancer	0.000372	0.00194	CcSEcCtD
Trihexyphenidyl—Asthenia—Thiotepa—breast cancer	0.000371	0.00193	CcSEcCtD
Trihexyphenidyl—Nausea—Melphalan—breast cancer	0.000368	0.00192	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Mitoxantrone—breast cancer	0.000368	0.00192	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Irinotecan—breast cancer	0.000368	0.00192	CcSEcCtD
Trihexyphenidyl—Confusional state—Paclitaxel—breast cancer	0.000367	0.00191	CcSEcCtD
Trihexyphenidyl—Dry skin—Doxorubicin—breast cancer	0.00036	0.00187	CcSEcCtD
Trihexyphenidyl—Nausea—Goserelin—breast cancer	0.000359	0.00187	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Gemcitabine—breast cancer	0.000359	0.00187	CcSEcCtD
Trihexyphenidyl—Dizziness—Vinorelbine—breast cancer	0.000358	0.00186	CcSEcCtD
Trihexyphenidyl—Tachycardia—Paclitaxel—breast cancer	0.000356	0.00185	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Fluorouracil—breast cancer	0.000353	0.00183	CcSEcCtD
Trihexyphenidyl—Oxybutynin—CYP3A4—breast cancer	0.000351	0.211	CrCbGaD
Trihexyphenidyl—Drowsiness—Methotrexate—breast cancer	0.000349	0.00182	CcSEcCtD
Trihexyphenidyl—Vision blurred—Capecitabine—breast cancer	0.000345	0.0018	CcSEcCtD
Trihexyphenidyl—Vomiting—Vinorelbine—breast cancer	0.000344	0.00179	CcSEcCtD
Trihexyphenidyl—Dizziness—Thiotepa—breast cancer	0.000342	0.00178	CcSEcCtD
Trihexyphenidyl—Rash—Vinorelbine—breast cancer	0.000342	0.00178	CcSEcCtD
Trihexyphenidyl—Dermatitis—Vinorelbine—breast cancer	0.000341	0.00178	CcSEcCtD
Trihexyphenidyl—Headache—Vinorelbine—breast cancer	0.000339	0.00177	CcSEcCtD
Trihexyphenidyl—Weight decreased—Epirubicin—breast cancer	0.000331	0.00172	CcSEcCtD
Trihexyphenidyl—Vomiting—Thiotepa—breast cancer	0.000329	0.00171	CcSEcCtD
Trihexyphenidyl—Drowsiness—Epirubicin—breast cancer	0.000327	0.0017	CcSEcCtD
Trihexyphenidyl—Rash—Thiotepa—breast cancer	0.000326	0.0017	CcSEcCtD
Trihexyphenidyl—Dermatitis—Thiotepa—breast cancer	0.000326	0.0017	CcSEcCtD
Trihexyphenidyl—Headache—Thiotepa—breast cancer	0.000324	0.00169	CcSEcCtD
Trihexyphenidyl—Somnolence—Paclitaxel—breast cancer	0.000324	0.00169	CcSEcCtD
Trihexyphenidyl—Nausea—Vinorelbine—breast cancer	0.000322	0.00167	CcSEcCtD
Trihexyphenidyl—Asthenia—Mitoxantrone—breast cancer	0.000321	0.00167	CcSEcCtD
Trihexyphenidyl—Asthenia—Irinotecan—breast cancer	0.000321	0.00167	CcSEcCtD
Trihexyphenidyl—Asthenia—Gemcitabine—breast cancer	0.000312	0.00162	CcSEcCtD
Trihexyphenidyl—Constipation—Paclitaxel—breast cancer	0.000312	0.00162	CcSEcCtD
Trihexyphenidyl—Confusional state—Docetaxel—breast cancer	0.000311	0.00162	CcSEcCtD
Trihexyphenidyl—Nausea—Thiotepa—breast cancer	0.000307	0.0016	CcSEcCtD
Trihexyphenidyl—Weight decreased—Doxorubicin—breast cancer	0.000307	0.0016	CcSEcCtD
Trihexyphenidyl—Drowsiness—Doxorubicin—breast cancer	0.000302	0.00157	CcSEcCtD
Trihexyphenidyl—Confusional state—Capecitabine—breast cancer	0.000302	0.00157	CcSEcCtD
Trihexyphenidyl—Tachycardia—Docetaxel—breast cancer	0.000301	0.00157	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Paclitaxel—breast cancer	0.0003	0.00156	CcSEcCtD
Trihexyphenidyl—Dizziness—Irinotecan—breast cancer	0.000295	0.00154	CcSEcCtD
Trihexyphenidyl—Tachycardia—Capecitabine—breast cancer	0.000292	0.00152	CcSEcCtD
Trihexyphenidyl—Vomiting—Mitoxantrone—breast cancer	0.000284	0.00148	CcSEcCtD
Trihexyphenidyl—Vomiting—Irinotecan—breast cancer	0.000284	0.00148	CcSEcCtD
Trihexyphenidyl—Dizziness—Fluorouracil—breast cancer	0.000283	0.00147	CcSEcCtD
Trihexyphenidyl—Rash—Irinotecan—breast cancer	0.000282	0.00147	CcSEcCtD
Trihexyphenidyl—Rash—Mitoxantrone—breast cancer	0.000282	0.00147	CcSEcCtD
Trihexyphenidyl—Dermatitis—Mitoxantrone—breast cancer	0.000281	0.00146	CcSEcCtD
Trihexyphenidyl—Dermatitis—Irinotecan—breast cancer	0.000281	0.00146	CcSEcCtD
Trihexyphenidyl—Headache—Irinotecan—breast cancer	0.00028	0.00146	CcSEcCtD
Trihexyphenidyl—Headache—Mitoxantrone—breast cancer	0.00028	0.00146	CcSEcCtD
Trihexyphenidyl—Vomiting—Gemcitabine—breast cancer	0.000277	0.00144	CcSEcCtD
Trihexyphenidyl—Somnolence—Docetaxel—breast cancer	0.000275	0.00143	CcSEcCtD
Trihexyphenidyl—Rash—Gemcitabine—breast cancer	0.000274	0.00143	CcSEcCtD
Trihexyphenidyl—Dermatitis—Gemcitabine—breast cancer	0.000274	0.00143	CcSEcCtD
Trihexyphenidyl—Headache—Gemcitabine—breast cancer	0.000273	0.00142	CcSEcCtD
Trihexyphenidyl—Vomiting—Fluorouracil—breast cancer	0.000272	0.00142	CcSEcCtD
Trihexyphenidyl—Rash—Fluorouracil—breast cancer	0.00027	0.0014	CcSEcCtD
Trihexyphenidyl—Dermatitis—Fluorouracil—breast cancer	0.00027	0.0014	CcSEcCtD
Trihexyphenidyl—Headache—Fluorouracil—breast cancer	0.000268	0.00139	CcSEcCtD
Trihexyphenidyl—Nausea—Mitoxantrone—breast cancer	0.000265	0.00138	CcSEcCtD
Trihexyphenidyl—Nausea—Irinotecan—breast cancer	0.000265	0.00138	CcSEcCtD
Trihexyphenidyl—Constipation—Docetaxel—breast cancer	0.000264	0.00137	CcSEcCtD
Trihexyphenidyl—Asthenia—Paclitaxel—breast cancer	0.000261	0.00136	CcSEcCtD
Trihexyphenidyl—Nausea—Gemcitabine—breast cancer	0.000259	0.00135	CcSEcCtD
Trihexyphenidyl—Vision blurred—Methotrexate—breast cancer	0.000257	0.00134	CcSEcCtD
Trihexyphenidyl—Constipation—Capecitabine—breast cancer	0.000256	0.00133	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Docetaxel—breast cancer	0.000255	0.00132	CcSEcCtD
Trihexyphenidyl—Nausea—Fluorouracil—breast cancer	0.000254	0.00132	CcSEcCtD
Trihexyphenidyl—Tension—Epirubicin—breast cancer	0.000251	0.0013	CcSEcCtD
Trihexyphenidyl—Nervousness—Epirubicin—breast cancer	0.000248	0.00129	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Capecitabine—breast cancer	0.000246	0.00128	CcSEcCtD
Trihexyphenidyl—Dizziness—Paclitaxel—breast cancer	0.000241	0.00125	CcSEcCtD
Trihexyphenidyl—Vision blurred—Epirubicin—breast cancer	0.000241	0.00125	CcSEcCtD
Trihexyphenidyl—Agitation—Epirubicin—breast cancer	0.000235	0.00122	CcSEcCtD
Trihexyphenidyl—Tension—Doxorubicin—breast cancer	0.000232	0.00121	CcSEcCtD
Trihexyphenidyl—Vomiting—Paclitaxel—breast cancer	0.000232	0.00121	CcSEcCtD
Trihexyphenidyl—Rash—Paclitaxel—breast cancer	0.00023	0.0012	CcSEcCtD
Trihexyphenidyl—Dermatitis—Paclitaxel—breast cancer	0.00023	0.00119	CcSEcCtD
Trihexyphenidyl—Nervousness—Doxorubicin—breast cancer	0.000229	0.00119	CcSEcCtD
Trihexyphenidyl—Headache—Paclitaxel—breast cancer	0.000228	0.00119	CcSEcCtD
Trihexyphenidyl—Confusional state—Methotrexate—breast cancer	0.000224	0.00117	CcSEcCtD
Trihexyphenidyl—Vision blurred—Doxorubicin—breast cancer	0.000223	0.00116	CcSEcCtD
Trihexyphenidyl—Asthenia—Docetaxel—breast cancer	0.000222	0.00115	CcSEcCtD
Trihexyphenidyl—Agitation—Doxorubicin—breast cancer	0.000217	0.00113	CcSEcCtD
Trihexyphenidyl—Nausea—Paclitaxel—breast cancer	0.000216	0.00113	CcSEcCtD
Trihexyphenidyl—Asthenia—Capecitabine—breast cancer	0.000215	0.00112	CcSEcCtD
Trihexyphenidyl—Confusional state—Epirubicin—breast cancer	0.00021	0.00109	CcSEcCtD
Trihexyphenidyl—Dizziness—Docetaxel—breast cancer	0.000204	0.00106	CcSEcCtD
Trihexyphenidyl—Tachycardia—Epirubicin—breast cancer	0.000203	0.00106	CcSEcCtD
Trihexyphenidyl—Somnolence—Methotrexate—breast cancer	0.000198	0.00103	CcSEcCtD
Trihexyphenidyl—Dizziness—Capecitabine—breast cancer	0.000198	0.00103	CcSEcCtD
Trihexyphenidyl—Vomiting—Docetaxel—breast cancer	0.000196	0.00102	CcSEcCtD
Trihexyphenidyl—Rash—Docetaxel—breast cancer	0.000195	0.00101	CcSEcCtD
Trihexyphenidyl—Dermatitis—Docetaxel—breast cancer	0.000195	0.00101	CcSEcCtD
Trihexyphenidyl—Confusional state—Doxorubicin—breast cancer	0.000194	0.00101	CcSEcCtD
Trihexyphenidyl—Headache—Docetaxel—breast cancer	0.000194	0.00101	CcSEcCtD
Trihexyphenidyl—Vomiting—Capecitabine—breast cancer	0.00019	0.000989	CcSEcCtD
Trihexyphenidyl—Rash—Capecitabine—breast cancer	0.000189	0.000981	CcSEcCtD
Trihexyphenidyl—Dermatitis—Capecitabine—breast cancer	0.000188	0.00098	CcSEcCtD
Trihexyphenidyl—Tachycardia—Doxorubicin—breast cancer	0.000188	0.000979	CcSEcCtD
Trihexyphenidyl—Headache—Capecitabine—breast cancer	0.000187	0.000975	CcSEcCtD
Trihexyphenidyl—Somnolence—Epirubicin—breast cancer	0.000185	0.000964	CcSEcCtD
Trihexyphenidyl—Nausea—Docetaxel—breast cancer	0.000183	0.000955	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Methotrexate—breast cancer	0.000183	0.000955	CcSEcCtD
Trihexyphenidyl—Constipation—Epirubicin—breast cancer	0.000178	0.000927	CcSEcCtD
Trihexyphenidyl—Nausea—Capecitabine—breast cancer	0.000178	0.000924	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Epirubicin—breast cancer	0.000172	0.000893	CcSEcCtD
Trihexyphenidyl—Somnolence—Doxorubicin—breast cancer	0.000171	0.000892	CcSEcCtD
Trihexyphenidyl—Constipation—Doxorubicin—breast cancer	0.000165	0.000858	CcSEcCtD
Trihexyphenidyl—Asthenia—Methotrexate—breast cancer	0.00016	0.000831	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Doxorubicin—breast cancer	0.000159	0.000827	CcSEcCtD
Trihexyphenidyl—Asthenia—Epirubicin—breast cancer	0.000149	0.000778	CcSEcCtD
Trihexyphenidyl—Dizziness—Methotrexate—breast cancer	0.000147	0.000766	CcSEcCtD
Trihexyphenidyl—Vomiting—Methotrexate—breast cancer	0.000142	0.000737	CcSEcCtD
Trihexyphenidyl—Rash—Methotrexate—breast cancer	0.00014	0.00073	CcSEcCtD
Trihexyphenidyl—Dermatitis—Methotrexate—breast cancer	0.00014	0.00073	CcSEcCtD
Trihexyphenidyl—Headache—Methotrexate—breast cancer	0.000139	0.000726	CcSEcCtD
Trihexyphenidyl—Asthenia—Doxorubicin—breast cancer	0.000138	0.00072	CcSEcCtD
Trihexyphenidyl—Dizziness—Epirubicin—breast cancer	0.000138	0.000717	CcSEcCtD
Trihexyphenidyl—Vomiting—Epirubicin—breast cancer	0.000132	0.000689	CcSEcCtD
Trihexyphenidyl—Nausea—Methotrexate—breast cancer	0.000132	0.000688	CcSEcCtD
Trihexyphenidyl—Rash—Epirubicin—breast cancer	0.000131	0.000684	CcSEcCtD
Trihexyphenidyl—Dermatitis—Epirubicin—breast cancer	0.000131	0.000683	CcSEcCtD
Trihexyphenidyl—Headache—Epirubicin—breast cancer	0.000131	0.000679	CcSEcCtD
Trihexyphenidyl—Dizziness—Doxorubicin—breast cancer	0.000127	0.000663	CcSEcCtD
Trihexyphenidyl—Nausea—Epirubicin—breast cancer	0.000124	0.000644	CcSEcCtD
Trihexyphenidyl—Vomiting—Doxorubicin—breast cancer	0.000123	0.000638	CcSEcCtD
Trihexyphenidyl—Rash—Doxorubicin—breast cancer	0.000122	0.000632	CcSEcCtD
Trihexyphenidyl—Dermatitis—Doxorubicin—breast cancer	0.000121	0.000632	CcSEcCtD
Trihexyphenidyl—Headache—Doxorubicin—breast cancer	0.000121	0.000628	CcSEcCtD
Trihexyphenidyl—Nausea—Doxorubicin—breast cancer	0.000115	0.000596	CcSEcCtD
Trihexyphenidyl—CHRM4—Signaling Pathways—RAF1—breast cancer	1.22e-05	0.000116	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—RELA—breast cancer	1.22e-05	0.000116	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGFR1—breast cancer	1.21e-05	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—ERBB2—breast cancer	1.21e-05	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGFR1—breast cancer	1.21e-05	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGFR1—breast cancer	1.2e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MTOR—breast cancer	1.19e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CB—breast cancer	1.19e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—HIF1A—breast cancer	1.19e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—HIF1A—breast cancer	1.19e-05	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—PIK3CA—breast cancer	1.18e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—HIF1A—breast cancer	1.18e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MDM2—breast cancer	1.18e-05	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—RAF1—breast cancer	1.17e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—RELA—breast cancer	1.17e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LEP—breast cancer	1.16e-05	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LEP—breast cancer	1.16e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—ERBB2—breast cancer	1.16e-05	0.00011	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CAV1—breast cancer	1.15e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CAV1—breast cancer	1.15e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LEP—breast cancer	1.15e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CXCL8—breast cancer	1.15e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MTOR—breast cancer	1.14e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CB—breast cancer	1.14e-05	0.000109	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KDR—breast cancer	1.14e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—HRAS—breast cancer	1.14e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CAV1—breast cancer	1.14e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KDR—breast cancer	1.14e-05	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KDR—breast cancer	1.13e-05	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CDKN1B—breast cancer	1.12e-05	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ESR1—breast cancer	1.11e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—AKT1—breast cancer	1.11e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ESR1—breast cancer	1.11e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CD—breast cancer	1.1e-05	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CXCL8—breast cancer	1.1e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CASP3—breast cancer	1.1e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FN1—breast cancer	1.1e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ESR1—breast cancer	1.1e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL2—breast cancer	1.1e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FN1—breast cancer	1.09e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—HRAS—breast cancer	1.09e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—breast cancer	1.09e-05	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ALB—breast cancer	1.09e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NFKBIA—breast cancer	1.08e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FN1—breast cancer	1.08e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NFKBIA—breast cancer	1.08e-05	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOTCH1—breast cancer	1.07e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CDKN1B—breast cancer	1.07e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOTCH1—breast cancer	1.07e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NFKBIA—breast cancer	1.07e-05	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCND1—breast cancer	1.07e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—JUN—breast cancer	1.07e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—AKT1—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOTCH1—breast cancer	1.06e-05	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CTNNB1—breast cancer	1.06e-05	0.0001	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CASP3—breast cancer	1.05e-05	9.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APC—breast cancer	1.05e-05	9.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KIT—breast cancer	1.05e-05	9.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CG—breast cancer	1.05e-05	9.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL2—breast cancer	1.05e-05	9.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KIT—breast cancer	1.05e-05	9.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CG—breast cancer	1.05e-05	9.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APC—breast cancer	1.05e-05	9.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—breast cancer	1.04e-05	9.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—NOS3—breast cancer	1.04e-05	9.87e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EGF—breast cancer	1.04e-05	9.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MMP9—breast cancer	1.04e-05	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KIT—breast cancer	1.04e-05	9.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CG—breast cancer	1.04e-05	9.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APC—breast cancer	1.04e-05	9.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EGF—breast cancer	1.04e-05	9.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CDKN1A—breast cancer	1.03e-05	9.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PTEN—breast cancer	1.03e-05	9.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EGF—breast cancer	1.03e-05	9.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCND1—breast cancer	1.02e-05	9.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—JUN—breast cancer	1.02e-05	9.7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CTNNB1—breast cancer	1.01e-05	9.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MAPK8—breast cancer	1.01e-05	9.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—AKT1—breast cancer	1.01e-05	9.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—MAPK3—breast cancer	1.01e-05	9.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—MAPK3—breast cancer	1e-05	9.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MMP9—breast cancer	9.94e-06	9.43e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—MAPK3—breast cancer	9.93e-06	9.43e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CDKN1A—breast cancer	9.9e-06	9.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PTEN—breast cancer	9.88e-06	9.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—BRAF—breast cancer	9.88e-06	9.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—BRAF—breast cancer	9.84e-06	9.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—BRAF—breast cancer	9.75e-06	9.25e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MAPK8—breast cancer	9.67e-06	9.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—AKT1—breast cancer	9.64e-06	9.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF1—breast cancer	9.62e-06	9.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT2—breast cancer	9.61e-06	9.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CB—breast cancer	9.6e-06	9.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF1—breast cancer	9.59e-06	9.1e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT2—breast cancer	9.58e-06	9.1e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—EGFR—breast cancer	9.57e-06	9.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SRC—breast cancer	9.57e-06	9.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—EGFR—breast cancer	9.54e-06	9.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTGS2—breast cancer	9.51e-06	9.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF1—breast cancer	9.5e-06	9.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT2—breast cancer	9.49e-06	9.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—EGFR—breast cancer	9.45e-06	8.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—VEGFA—breast cancer	9.32e-06	8.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CD—breast cancer	9.24e-06	8.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—STAT3—breast cancer	9.23e-06	8.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CD—breast cancer	9.21e-06	8.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SRC—breast cancer	9.16e-06	8.7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	9.15e-06	8.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SERPINE1—breast cancer	9.14e-06	8.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	9.12e-06	8.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CD—breast cancer	9.12e-06	8.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SERPINE1—breast cancer	9.11e-06	8.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—KRAS—breast cancer	9.04e-06	8.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	9.03e-06	8.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SERPINE1—breast cancer	9.02e-06	8.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—KRAS—breast cancer	9.01e-06	8.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—KRAS—breast cancer	8.93e-06	8.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—VEGFA—breast cancer	8.92e-06	8.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—STAT3—breast cancer	8.84e-06	8.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MAPK3—breast cancer	8.82e-06	8.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOS3—breast cancer	8.72e-06	8.28e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOS3—breast cancer	8.69e-06	8.25e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOS3—breast cancer	8.61e-06	8.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MYC—breast cancer	8.57e-06	8.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TGFB1—breast cancer	8.55e-06	8.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MAPK3—breast cancer	8.44e-06	8.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—EGFR—breast cancer	8.39e-06	7.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	8.31e-06	7.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTEN—breast cancer	8.29e-06	7.87e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	8.28e-06	7.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MDM2—breast cancer	8.27e-06	7.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MDM2—breast cancer	8.25e-06	7.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RAF1—breast cancer	8.25e-06	7.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RAF1—breast cancer	8.22e-06	7.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MYC—breast cancer	8.21e-06	7.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RELA—breast cancer	8.21e-06	7.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	8.2e-06	7.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TGFB1—breast cancer	8.19e-06	7.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RELA—breast cancer	8.18e-06	7.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MDM2—breast cancer	8.17e-06	7.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ERBB2—breast cancer	8.16e-06	7.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RAF1—breast cancer	8.14e-06	7.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ERBB2—breast cancer	8.13e-06	7.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RELA—breast cancer	8.1e-06	7.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ERBB2—breast cancer	8.05e-06	7.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MTOR—breast cancer	8.05e-06	7.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CB—breast cancer	8.05e-06	7.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—EGFR—breast cancer	8.03e-06	7.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CB—breast cancer	8.02e-06	7.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MTOR—breast cancer	8.02e-06	7.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MTOR—breast cancer	7.95e-06	7.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CB—breast cancer	7.95e-06	7.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—KRAS—breast cancer	7.92e-06	7.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CXCL8—breast cancer	7.74e-06	7.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CXCL8—breast cancer	7.71e-06	7.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—HRAS—breast cancer	7.69e-06	7.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—HRAS—breast cancer	7.66e-06	7.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CXCL8—breast cancer	7.64e-06	7.25e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—HRAS—breast cancer	7.59e-06	7.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—KRAS—breast cancer	7.59e-06	7.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN1B—breast cancer	7.56e-06	7.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN1B—breast cancer	7.53e-06	7.15e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—AKT1—breast cancer	7.47e-06	7.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN1B—breast cancer	7.46e-06	7.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—AKT1—breast cancer	7.45e-06	7.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CASP3—breast cancer	7.4e-06	7.03e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL2—breast cancer	7.39e-06	7.02e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CASP3—breast cancer	7.38e-06	7.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—AKT1—breast cancer	7.38e-06	7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL2—breast cancer	7.37e-06	7e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—breast cancer	7.36e-06	6.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—breast cancer	7.33e-06	6.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CASP3—breast cancer	7.31e-06	6.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL2—breast cancer	7.3e-06	6.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3CA—breast cancer	7.28e-06	6.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—breast cancer	7.26e-06	6.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCND1—breast cancer	7.21e-06	6.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—JUN—breast cancer	7.19e-06	6.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCND1—breast cancer	7.18e-06	6.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—JUN—breast cancer	7.17e-06	6.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CTNNB1—breast cancer	7.14e-06	6.77e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCND1—breast cancer	7.11e-06	6.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CTNNB1—breast cancer	7.11e-06	6.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—JUN—breast cancer	7.1e-06	6.74e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CTNNB1—breast cancer	7.05e-06	6.69e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TP53—breast cancer	7.04e-06	6.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MMP9—breast cancer	7e-06	6.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MMP9—breast cancer	6.98e-06	6.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN1A—breast cancer	6.97e-06	6.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3CA—breast cancer	6.97e-06	6.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTEN—breast cancer	6.96e-06	6.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN1A—breast cancer	6.95e-06	6.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTEN—breast cancer	6.93e-06	6.58e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MMP9—breast cancer	6.91e-06	6.56e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN1A—breast cancer	6.88e-06	6.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTEN—breast cancer	6.87e-06	6.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAPK8—breast cancer	6.81e-06	6.46e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—AKT1—breast cancer	6.79e-06	6.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAPK8—breast cancer	6.78e-06	6.44e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—AKT1—breast cancer	6.77e-06	6.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TP53—breast cancer	6.74e-06	6.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—HRAS—breast cancer	6.73e-06	6.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAPK8—breast cancer	6.72e-06	6.38e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—AKT1—breast cancer	6.7e-06	6.36e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SRC—breast cancer	6.45e-06	6.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—HRAS—breast cancer	6.45e-06	6.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—breast cancer	6.45e-06	6.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SRC—breast cancer	6.43e-06	6.1e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SRC—breast cancer	6.37e-06	6.04e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—VEGFA—breast cancer	6.28e-06	5.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—VEGFA—breast cancer	6.26e-06	5.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—STAT3—breast cancer	6.22e-06	5.91e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—VEGFA—breast cancer	6.2e-06	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—STAT3—breast cancer	6.2e-06	5.89e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—breast cancer	6.17e-06	5.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—STAT3—breast cancer	6.14e-06	5.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT1—breast cancer	5.95e-06	5.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MAPK3—breast cancer	5.94e-06	5.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MAPK3—breast cancer	5.93e-06	5.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MAPK3—breast cancer	5.87e-06	5.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3CA—breast cancer	5.85e-06	5.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MYC—breast cancer	5.78e-06	5.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFB1—breast cancer	5.77e-06	5.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MYC—breast cancer	5.76e-06	5.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFB1—breast cancer	5.75e-06	5.46e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MYC—breast cancer	5.71e-06	5.42e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT1—breast cancer	5.69e-06	5.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFB1—breast cancer	5.69e-06	5.4e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EGFR—breast cancer	5.65e-06	5.37e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EGFR—breast cancer	5.64e-06	5.35e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EGFR—breast cancer	5.58e-06	5.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KRAS—breast cancer	5.34e-06	5.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KRAS—breast cancer	5.32e-06	5.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KRAS—breast cancer	5.27e-06	5.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3CA—breast cancer	4.91e-06	4.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3CA—breast cancer	4.89e-06	4.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3CA—breast cancer	4.84e-06	4.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AKT1—breast cancer	4.78e-06	4.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TP53—breast cancer	4.75e-06	4.51e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TP53—breast cancer	4.73e-06	4.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TP53—breast cancer	4.69e-06	4.45e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—HRAS—breast cancer	4.54e-06	4.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—HRAS—breast cancer	4.53e-06	4.3e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—HRAS—breast cancer	4.48e-06	4.25e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—breast cancer	4.35e-06	4.12e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—breast cancer	4.33e-06	4.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—breast cancer	4.29e-06	4.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT1—breast cancer	4.01e-06	3.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT1—breast cancer	4e-06	3.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT1—breast cancer	3.96e-06	3.76e-05	CbGpPWpGaD
